Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) EBT (2016 - 2026)

Collegium Pharmaceutical has reported EBT over the past 10 years, most recently at $29.0 million for Q4 2025.

  • For Q4 2025, EBT rose 68.14% year-over-year to $29.0 million; the TTM value through Dec 2025 reached $92.6 million, down 6.04%, while the annual FY2025 figure was $92.6 million, 6.04% down from the prior year.
  • EBT for Q4 2025 was $29.0 million at Collegium Pharmaceutical, down from $43.4 million in the prior quarter.
  • Over five years, EBT peaked at $46.7 million in Q4 2023 and troughed at -$38.9 million in Q4 2021.
  • A 5-year average of $11.7 million and a median of $15.5 million in 2021 define the central range for EBT.
  • On a YoY basis, EBT climbed as much as 3338.67% in 2021 and fell as far as 635.33% in 2021.
  • Year by year, EBT stood at -$38.9 million in 2021, then skyrocketed by 79.96% to -$7.8 million in 2022, then surged by 699.54% to $46.7 million in 2023, then tumbled by 63.03% to $17.3 million in 2024, then soared by 68.14% to $29.0 million in 2025.
  • Business Quant data shows EBT for COLL at $29.0 million in Q4 2025, $43.4 million in Q3 2025, and $17.0 million in Q2 2025.